Publications by authors named "Christopher C Goodis"

Claim this Profile
A
Augmenting the Anti-Leukemic Activity of the BCL-2 Inhibitor Venetoclax Through Its Transformation Into Polypharmacologic Dual BCL-2/HDAC1 and Dual BCL-2/HDAC6 Inhibitors.
Alexandria M Chan, Christian Eberly, Brandon Drennen, Christopher C Goodis, Zoe Wuyts

Drug Dev Res· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The polypharmacy combination of the BCL-2 inhibitor venetoclax (VEN) and the FLT3 inhibitor gilteritinib (GIL) is more active in acute myeloid leukemia cells than novel polypharmacologic BCL-2/FLT3 VEN-GIL hybrid single-molecule inhibitors.
Christopher C Goodis, Christian Eberly, Alexandria M Chan, MinJung Kim, Brandon D Lowe

Eur J Med Chem· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multimodal nanoparticle-containing modified suberoylanilide hydroxamic acid polymer conjugates to mitigate immune dysfunction in severe inflammation.
Nhu Truong, Andrea L Cottingham, Shruti Dharmaraj, Jacob R Shaw, Jackline Joy Martin Lasola, Christopher C Goodis

Bioeng Transl Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of -sulfonylated aminosalicylic acids as dual MCL-1/BCL-xL inhibitors.
Lijia Chen, Jay Chauhan, Jeremy L Yap, Christopher C Goodis, Paul T Wilder

RSC Med Chem· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modified Suberoylanilide Hydroxamic Acid Reduced Drug-Associated Immune Cell Death and Organ Damage under Lipopolysaccharide Inflammatory Challenge.
Nhu Truong, Christopher C Goodis, Andrea L Cottingham, Jacob R Shaw, Steven Fletcher

ACS Pharmacol Transl Sci· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent applications of covalent chemistries in protein-protein interaction inhibitors.
Alexandria M Chan, Christopher C Goodis, Elie G Pommier, Steven Fletcher

RSC Med Chem· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Scaffold hopping from indoles to indazoles yields dual MCL-1/BCL-2 inhibitors from MCL-1 selective leads.
Brandon Drennen, Christopher C Goodis, Nathan Bowen, Wenbo Yu, Gregory Vickers

RSC Med Chem· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis